J.P. MORGAN
Healthcare Conference
Prahlad Singh
Chief Executive Officer
January 11, 2022
1
SAFE HARBOR
This presentation contains "forward-looking" statements which are statements relating to future events. These statements include those relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. A detailed description of these risk factors can be found under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.
In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. A reconciliation of these measures to the most directly comparable GAAP measures is included in the embedded hyperlinkand is available on the "Investor Events" section of our investor relations website at ir.perkinelmer.com.
Guidance for future periods is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company's results prepared in accordance with GAAP.
2
WHO WE ARE
OUR MISSION
Diagnostics
INNOVATING
Life Sciences
for a
healthier
Food
WORLD
Applied
Passionate about saving and transforming patients' lives
Focused on accelerating pre-clinical discoveries and enabling customers to deliver safe and effective therapies
Dedicated to ensuring the highest quality product and keeping the consumer safe
Energized by empowering a cleaner
and safer environment
3
PERKINELMER TODAY
Diagnostics
(Dx)
$5.0B
2021e
revenue
Discovery &
Analytical
Solutions
(DAS)
>16,000 Employees Strong
Portfolio Mix* | |||||
Consumables, | |||||
~45% | ~25% | Services, | |||
Software | |||||
Americas | Asia | ||||
~30% | ~80% | ||||
Europe | |||||
Instruments | |||||
~20% | |||||
2021 Performance† : Continued to Deliver Record Results
Non-COVID | COVID | Adj. EPS |
Organic Growth | Revenue | Growth |
16% | >$1.5B | 30%+ |
Vs. 2020 | Vs. 2020 |
* YTD through 3Q'21; † Reconciliations of these non-GAAP items to GAAP are provided on our website and here (link)
4
WHAT YOU'LL HEAR TODAY
THE NEW PERKINELMER
Transformation Enabling Faster
Growth and Greater Value Creation
1. | ATTRACTIVE & | Providing complete |
EXPANDED PORTFOLIO | solutions across Dx and LS | |
2. | FOCUSED INTERNAL | Clear progress across |
EXECUTION | four strategic priorities | |
3. | STRONG | Delivering results and |
FINANCIAL OUTLOOK | improved financial profile | |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
PerkinElmer Inc. published this content on 11 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 11 January 2022 17:37:09 UTC.